| Similar Articles |
|---|
 |
Bio-IT World
April 2007
Vicki Glaser |
Software Solutions for Medicinal Chemistry Driven by advances in chemical synthesis, instrumentation, and high-throughput and high-content screening technology, medicinal chemistry's transition from an art to a science is benefiting from a wealth of new software products, spanning both bio- and cheminformatics.   |
Bio-IT World
February 10, 2003
Malorye Branca |
Conquering Infinity with Chemical Genetics Harvard superchemist Stuart Schreiber defines the convergence of chemistry and biology. Now the field of chemical genetics is heading toward the clinic. |
Bio-IT World
April 15, 2003
Mark D. Uehling |
Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials. |
Pharmaceutical Executive
July 1, 2005
Zaborowski, Hammer & Lawler |
Informatics Rules How global computer systems helped far-flung research centers at Roche work together |
Bio-IT World
September 2006
Kevin Davies |
Pfizer's Global Survey of Pharmacological Space The pharma blends knowledge, computational chemistry and research informatics to build a unified database. Gathering all the data in one place offered greater control for indexing and data retrieval and management, enabling Pfizer scientists to perform global mapping. |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
Bio-IT World
January 21, 2005 |
Defining 'Integrative Genomics' Five experts from academia and industry discuss the burgeoning field of integrative genomics. |
Bio-IT World
March 10, 2003
Mark D. Uehling |
Technology Overload Inundated with new IT tools and mountains of data, the pharmaceutical industry struggles to pull it all together. |
Pharmaceutical Executive
February 1, 2006
Ron Feemster |
Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets. |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
Bio-IT World
November 2006
Robert M. Frederickson |
Managing Data on the Go GeneGo has created a suite of software and database products that aim to facilitate analysis of the biology behind different types of high-throughput experimentation and understand the effects of small molecule drug compounds in human tissues. |
Chemistry World
August 13, 2015 |
Exploiting the data mine Chemists must embrace open data to allow us to collectively get the best out of the masses of new knowledge we unearth, reports Clare Sansom |
Bio-IT World
September 2006
Mike May |
Working Out the Flow Better management of workflow issues in biotech and pharma could change fundamental aspects of these sciences in the near future. |
Bio-IT World
April 2006
John Russell |
Pfizer's Pursuit of Technology Can this $50-billion-plus, 115,000-employee behemoth succeed where other pharma giants have failed and successfully institutionalize the effort to find and develop critical new technology? Should it even try? |
Bio-IT World
September 9, 2002
John P. Helfrich |
Data Management in High-Throughput Screening The high-throughput drug discovery field requires an optimal IT platform. |
Bio-IT World
December 15, 2003
Malorye A. Branca |
Scenes from a Cell Breakthroughs are making cell-based screening faster, easier, more powerful. |
| Knowledge@Wharton |
A New Approach to Valuing Biotech Stocks Enormous swings in biotechnology stock prices during the last few weeks show how difficult it is for investors to value biotech companies. It's important to understand the invisible potential locked up in the organizational structure of biotechnology companies... |
Reactive Reports
Issue 55
David Bradley |
Interview with Wendy Warr This well-known and well-respected expert in the field of chemical information creates online reports and opinions that are essential reading for chemists hoping to understand the changes in information that are currently underway. |
Bio-IT World
November 2006
Kevin Davies |
Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights. |
Bio-IT World
August 18, 2004 |
Project Summaries Drug Discovery and Development: Ace BioSciences... Compugen... Entelos/Organon... Iconix Pharmaceuticals... Johnson & Johnson Pharmaceutical Research & Development... Laboratoire Kastler Brossel ... etc. |
Chemistry World
June 2008
Sarah Houlton |
Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success |
Chemistry World
June 2011 |
Column: In the pipeline Chemists are human. Humans are hierarchical. Therefore...well, therefore, you'll find a number of different roles and levels for scientists in a drug company's labs. Here's a rough ordering, from least experienced to most. |
Information Today
September 10, 2001
Robert E. Buntrock |
CAS Announces New Features and Improvements at Recent ACS Meeting Although these developments are of primary importance to chemists, I should point out that chemistry is indeed "the central science." Both the science and its unique information-handling challenges are relevant to applications and technologies affecting all of us... |
Bio-IT World
March 2007
Kevin Davies |
Leading by Example At Cambridge Healthtech Institute's annual Pharmaceutical and Biotech Leader's Summit, drug industry executives provided accounts of the profound organizational and technological changes that are helping organizations overcome industry-wide challenges. |
Bio-IT World
June 12, 2002
Morris R. Levitt |
A New Economic Paradigm for Bio-IT? All who work in the bio-IT industry -- scientists, IT and informatics managers, and executives -- have been aware for some time that we seem to be suspended between an acute sense of crisis and a field of boundless opportunity. |
HHMI Bulletin
Nov 2011
Sarah C. P. Williams |
Living Chemistry Biologists understand better what chemists can bring to the table. And chemists understand better the questions that biologists really care about. This has led to a bigger impact of chemists on biological problems. |
Chemistry World
April 25, 2013
Andreas Barth |
Chemical bibliometrics Counting compounds instead of publications and citations opens new perspectives for data-based scientific discovery and it can complement and stimulate both experimental and theoretical research. |
Reactive Reports
Issue 57 |
Interview with Andrew Lemon With a background in Chemistry and a keen sense of business, this co-found of The Edge Software Consultancy helps global pharmaceutical companies increase the efficiency and productivity of their software tools. |
Bio-IT World
Dec 2006/Jan 2007
Kevin Davies |
The NextBio Thing in Bioinformatics NextBio, which this fall officially introduced its platform after a year of beta testing by a handful of select organizations, aims to provide high-throughput information to researchers without them having to learn anything. |
Chemistry World
August 2007
Derek Lowe |
Opinion: In the Pipeline Process chemists just don't get the credit they deserve. |
Bio-IT World
October 14, 2004
Salvatore Salamone |
Riding the New Wave New offerings from Accelrys, LION bioscience, MDL, Synthematix, and Tripos may be the crest of a new wave of software designed to meet increasing demand to incorporate chemoinformatics into the drug discovery process. |
Chemistry World
July 26, 2012
Derek Lowe |
Screen shots You might not think that the makeup of a compound screening collection could set off many arguments, but there are a few issues there that will do the trick almost every time. |
Information Today
February 13, 2012 |
Elsevier Launches TargetInsights for Early Drug Discovery This online decision support tool enables scientists to search, monitor, and stay up-to-date with the latest biological insights reported in the scientific literature. |
| Chemistry World |
Fishing for Chemical Answers to Biological Questions James K. Chen talks about chemical biology, his love for the outdoors and fly fishing. |
Chemistry World
December 2008 |
Column: In the pipeline I've worked on two drug discovery efforts (one right after the other, as fate would have it) whose final compounds differed by essentially one methyl group from the starting points of each project. |
Chemistry World
June 1, 2012
Derek Lowe |
Peace, love and understanding You'd think that the chemists and biologists working in drug discovery would understand each other pretty well by now. You would be wrong about that. |
Chemistry World
July 2008
Kevin Rogers |
What future for small molecule therapy? Pharmaceutical companies overlook bench chemists at their peril |
Bio-IT World
August 13, 2002
Russell & Dodge |
Necessary Liaisons: Making Standards Work Caroline Kovac, IBM Corp.'s general manager for life sciences, talks about the need for standards and her take on the troubled informatics world. |
Chemistry World
October 2010 |
Column: In the pipeline Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery |
Bio-IT World
September 16, 2004
Michael A. Greeley |
Platforms for Pathways Investor interest in the next great blockbuster drug has been blistering hot; Phase II and Phase III compound companies are being funded at a near record-breaking pace now that the IPO window seems to be slightly open |
Bio-IT World
September 2006
John Russell |
Informatics Cornucopia Predictive Informatics, the hopeful title of a session at last month's Drug Discovery Technology & Development World Congress, remains an enticing but mostly elusive goal. Asked what systems biology would look in five years and what will constitute success, panelists offered the following. |
Reactive Reports
December 2006
David Bradley |
Dick Wife An interview with the chemical IT scientist and co-founder of SORD, a scientific publishing company that seeks to solve the problem of organizing the myriad of undocumented chemistry and the chaotic mess of the commercial database. |
HHMI Bulletin
Nov 2011
Sarah C.P. Williams. |
Carolyn Bertozzi: Changed Expectations Chemists trained in biology were once a rarity -- now they're becoming the norm. |
Chemistry World
December 2007
Richard Van Noorden |
Surfing Web2O The rapid evolution of the world wide web is creating fresh opportunities - and challenges - for chemistry. |
Chemistry World
October 2008
Derek Lowe |
Column: In the pipeline The author seeks a cure for 'compound bloat' |
Reactive Reports
November 2005
David Bradley |
Peter Murray-Rust An interview with the scientific software developer, originally a crystallographer with a DPhil from Oxford, on how he is now helping to establish novel software and Web technologies for chemists and other scientists underpinned by the concept of open source. |
Chemistry World
January 2012 |
Rising interest in compound bank David Fox argues for the creation of a centralized repository for small molecules to harness research efforts in drug discovery |
Bio-IT World
November 2005 |
Bridges and Boundaries in Drug Discovery Research Good communication, blurring cultural boundaries, and strong project governance may be as, if not more, important as sweeping technology solutions when it comes to converging discovery and IT and expediting drug development. |
Bio-IT World
November 2005
Kevin Davies |
A Win-Win Situation The inaugural Bridging Discovery and IT conference explored critical issues facing discovery, clinical, and IT teams struggling to communicate and collaborate in biopharma organizations. |
Chemistry World
January 2008
Philip Ball |
Column: The Crucible Does chemical space limit a chemists' creativity? |
